Spots Global Cancer Trial Database for malignant solid tumors
Every month we try and update this database with for malignant solid tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | NCT03205176 | Malignant Solid... Lymphoma Ovarian Cancer Breast Cancer Pancreatic Canc... Prostate Cancer | AZD5153 Olaparib | 18 Years - 130 Years | AstraZeneca | |
| Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis | NCT05305885 | Leptomeningeal ... | Pemetrexed Radiotherapy | 18 Years - 75 Years | The First Hospital of Jilin University | |
| PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy | NCT02805166 | Malignant Solid... | PEG-rhG-CSF | 18 Years - | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | |
| Characterization of Hyperpolarized Pyruvate MRI Reproducibility | NCT02421380 | Malignant Solid... | Hyperpolarized ... | 21 Years - 90 Years | Memorial Sloan Kettering Cancer Center | |
| Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors | NCT01765790 | Metastatic Aden... Malignant Solid... | Anti-Macrophage... Anti-Macrophage... | 18 Years - | Takeda | |
| tTF-NGR Phase I Study | NCT02902237 | Malignant Solid... Lymphomas | tTF-NGR | 18 Years - | University Hospital Muenster | |
| Characterization of Hyperpolarized Pyruvate MRI Reproducibility | NCT02421380 | Malignant Solid... | Hyperpolarized ... | 21 Years - 90 Years | Memorial Sloan Kettering Cancer Center | |
| A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | NCT06082557 | Malignant Solid... | T60c injection | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors | NCT03507244 | Leptomeningeal ... | Pemetrexed Dexamethasone Radiotherapy | 18 Years - 75 Years | The First Hospital of Jilin University | |
| Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors | NCT03507244 | Leptomeningeal ... | Pemetrexed Dexamethasone Radiotherapy | 18 Years - 75 Years | The First Hospital of Jilin University | |
| Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan | NCT00516438 | Malignant Solid... | KU-0059436 (AZD... Topotecan | 18 Years - | AstraZeneca | |
| Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors | NCT06150183 | Advanced Malign... | BNT314 Pembrolizumab | 18 Years - | BioNTech SE | |
| Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors | NCT05930457 | Malignant Solid... | 2.5-3.5mCi 64Cu... 3.5-4.5mCi 64Cu... 4.5-5.5mCi 64Cu... | 18 Years - | The First Affiliated Hospital of Guangzhou Medical University | |
| Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors | NCT05930457 | Malignant Solid... | 2.5-3.5mCi 64Cu... 3.5-4.5mCi 64Cu... 4.5-5.5mCi 64Cu... | 18 Years - | The First Affiliated Hospital of Guangzhou Medical University | |
| Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis | NCT05305885 | Leptomeningeal ... | Pemetrexed Radiotherapy | 18 Years - 75 Years | The First Hospital of Jilin University | |
| Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors | NCT05579275 | Malignant Solid... | JCXH-212 Inject... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan | NCT00516438 | Malignant Solid... | KU-0059436 (AZD... Topotecan | 18 Years - | AstraZeneca | |
| A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | NCT06082557 | Malignant Solid... | T60c injection | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors | NCT05579275 | Malignant Solid... | JCXH-212 Inject... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors | NCT06150183 | Advanced Malign... | BNT314 Pembrolizumab | 18 Years - | BioNTech SE | |
| Cancer Vaccine Targeting Brachyury Protein in Tumors | NCT01519817 | Neoplasms Malignant Solid... Colon Neoplasms Adenocarcinoma | GI-6301 (Yeast ... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Characterization of Hyperpolarized Pyruvate MRI Reproducibility | NCT02421380 | Malignant Solid... | Hyperpolarized ... | 21 Years - 90 Years | Memorial Sloan Kettering Cancer Center | |
| A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors | NCT05508620 | Malignant Solid... | Sirolimus for I... | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors | NCT00395434 | Tumors | Combretastatin ... Bevacizumab (Av... | 18 Years - | Mateon Therapeutics | |
| Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research | NCT05539677 | Malignant Solid... Primary Brain T... Melanoma Soft Tissue Sar... Colorectal Canc... Kidney Cancer Prostate Cancer | 1 Year - | N.N. Petrov National Medical Research Center of Oncology | ||
| Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors | NCT01694472 | Malignant Solid... | MAGE-A4 TCR Gen... | 18 Years - 80 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors | NCT03739827 | Malignant Solid... Other Neoplasms... Pediatric Solid... Refractory Soli... Solid Tumor | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors | NCT01765790 | Metastatic Aden... Malignant Solid... | Anti-Macrophage... Anti-Macrophage... | 18 Years - | Takeda | |
| An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib | NCT05594147 | Malignant Solid... Coronavirus Dis... SARS-CoV-2 Infe... | Non-TKIs Other TKIs Regorafenib (St... Sorafenib (Nexa... | 18 Years - | Bayer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
